Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus AXIRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus AXIRON.
ANDROID 10 vs AXIRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Testosterone replacement therapy; binds to androgen receptors, modulating gene expression and promoting protein synthesis, muscle growth, and secondary sexual characteristics.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
One or two pump actuations (30 mg per actuation) applied to the axilla once daily; dose range 30-90 mg daily.
None Documented
None Documented
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
The terminal elimination half-life of testosterone is approximately 10-100 minutes after intravenous injection, but for Axiron (testosterone topical solution), the apparent half-life is about 1-2 hours due to continued absorption from the skin and distribution/elimination. Clinically, steady state is achieved after about 2 weeks of daily application.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Testosterone is primarily excreted in urine as glucuronide and sulfate conjugates (about 90%) and about 6% in feces via bile. Approximately 90% of a dose is excreted in urine, with the remainder in feces.
Category C
Category C
Androgen
Androgen